The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2001
DOI: 10.1006/jmla.2000.2746
|View full text |Cite
|
Sign up to set email alerts
|

False Recognition in Triazolam-Induced Amnesia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0

Year Published

2003
2003
2021
2021

Publication Types

Select...
7
1
1

Relationship

2
7

Authors

Journals

citations
Cited by 17 publications
(10 citation statements)
references
References 47 publications
0
10
0
Order By: Relevance
“…The only significant procedural difference between the studies was that each study word was presented for 4 s in the Mintzer and Griffiths (2000a) study, and for 2 s in the present study amine dose (0.3 mg/70 kg) is consistent with the results of previous studies, and with Duka et al's (1996) observation that the investigation of scopolamine's effects on memory in healthy volunteers is limited to a narrow range of doses; whereas doses below 0.3 mg/70 kg typically do not produce significant effects, doses higher than 0.6 mg produce significant adverse effects (for example, hallucinations). In our second study with triazolam (Mintzer and Griffiths 2000b), we examined the effects of a single dose (0.25 mg/70 kg) on false recognition in the DRM paradigm in two experiments in which we varied the number of times lists were presented during study (once vs twice; experiment 1) and the number of associates presented in each list (6 vs 15; experiment 2). Results of the conditions which were directly comparable to those in Mintzer and Griffiths (2000a) and in the present study replicated the finding of decreased false recognition rates under drug conditions.…”
Section: Discussionmentioning
confidence: 99%
“…The only significant procedural difference between the studies was that each study word was presented for 4 s in the Mintzer and Griffiths (2000a) study, and for 2 s in the present study amine dose (0.3 mg/70 kg) is consistent with the results of previous studies, and with Duka et al's (1996) observation that the investigation of scopolamine's effects on memory in healthy volunteers is limited to a narrow range of doses; whereas doses below 0.3 mg/70 kg typically do not produce significant effects, doses higher than 0.6 mg produce significant adverse effects (for example, hallucinations). In our second study with triazolam (Mintzer and Griffiths 2000b), we examined the effects of a single dose (0.25 mg/70 kg) on false recognition in the DRM paradigm in two experiments in which we varied the number of times lists were presented during study (once vs twice; experiment 1) and the number of associates presented in each list (6 vs 15; experiment 2). Results of the conditions which were directly comparable to those in Mintzer and Griffiths (2000a) and in the present study replicated the finding of decreased false recognition rates under drug conditions.…”
Section: Discussionmentioning
confidence: 99%
“…There are some other evidences in the literature of conditions under which lorazepam can facilitate the retrieval of material learned when under the effect of the drug (eg File et al, 1999). Also, Mintzer and Griffiths (2001) showed that under the effects of another benzodiazepine, triazolam, memory performance improved when items were simply presented a second time. In our study, both lorazepam and placebo participants benefited from the second repetition.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, the quantitative dosing properties of drugs can be exploited to produce a graded amnesic effect in a dose-effect design. Findings of selective effects of drugs on particular aspects of memory performance but not others, or of dissociations between drugs, can provide converging evidence with data from nonpharmacological studies for the dissociability of specific processes or subcomponents (see Hirshman, Fisher, Henthorn, Arndt, & Passannante, 2002;Hirshman et al, 2001;Mintzer, 2003;Mintzer & Griffiths, 2001b). In addition, comparison of memory-impairing drugs with distinct neurochemical or pharmacological mechanisms of action can elucidate the brain mechanisms underlying specific cognitive processes.…”
mentioning
confidence: 90%